Children With Idiopathic Short Stature: An Expanding Role for Genetic Investigation in Their Medical Evaluation
- PMID: 38679385
- DOI: 10.1016/j.eprac.2024.04.009
Children With Idiopathic Short Stature: An Expanding Role for Genetic Investigation in Their Medical Evaluation
Abstract
Short stature in children is a common reason for referral to a pediatric endocrinologist. Many genetic, nutritional, psychological, illness-related, and hormonal causes must be excluded before labeling as idiopathic. Idiopathic short stature is not a diagnosis, but rather describes a large, heterogeneous group of children, who are short and often slowly growing. As new testing paradigms become available, the pool of patients labeled as idiopathic will shrink, although most will have a polygenic cause. Given that many of the new diagnoses are involved in growth plate biology, physical examination should assess for subtle dysmorphology or disproportion of the skeleton that may indicate a heterozygous mutation that in its homozygous state would be apparent. When laboratory evaluations are negative, one may consider genetic testing, such as targeted gene or gene panel, comparative genomic hybridization, or whole exome or whole genome sequencing (respectively). With a known genetic diagnosis, targeted therapy may be possible rather than recombinant human growth hormone, where response is generally poorer than that for children with growth hormone deficiency, because the variety of diagnoses may have varying growth hormone sensitivity. A firm diagnosis has heuristic value: to truncate further diagnostic evaluation, alert the clinician to other possible comorbidities, inform the family for genetic counseling, and direct appropriate targeted therapy, if available.
Keywords: aromatase inhibitors; genetic testing; growth; growth hormone; idiopathic short stature; sex steroids.
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure A.D.R. consults for Ascendis Pharma, Antares Pharma, BioMarin Pharmaceuticals, Pfizer Pharma, Tolmar Pharma, the United States Anti-Doping Agency (USADA), and the World Anti-Doping Agency (WADA). L.E.C. serves as a sub-PI (not receiving salary support) on investigator-initiated grant from Pfizer Global Medical Grant Growth Hormone Research to Boston Children’s Hospital. Site PI for Aeterna Zentaris.
Similar articles
-
Genetic evaluation in children with short stature.Curr Opin Pediatr. 2021 Aug 1;33(4):458-463. doi: 10.1097/MOP.0000000000001033. Curr Opin Pediatr. 2021. PMID: 34101704 Free PMC article. Review.
-
A polygenic score for height identifies an unmeasured genetic predisposition among pediatric patients with idiopathic short stature.Genome Med. 2025 Mar 19;17(1):23. doi: 10.1186/s13073-025-01455-3. Genome Med. 2025. PMID: 40108664 Free PMC article.
-
A new approach to the diagnosis of short stature.Minerva Pediatr. 2020 Aug;72(4):250-262. doi: 10.23736/S0026-4946.20.05835-1. Minerva Pediatr. 2020. PMID: 33045802 Review.
-
A genetic approach to evaluation of short stature of undetermined cause.Lancet Diabetes Endocrinol. 2018 Jul;6(7):564-574. doi: 10.1016/S2213-8587(18)30034-2. Epub 2018 Feb 1. Lancet Diabetes Endocrinol. 2018. PMID: 29397377 Review.
-
New Genetic Diagnoses of Short Stature Provide Insights into Local Regulation of Childhood Growth .Horm Res Paediatr. 2017;88(1):22-37. doi: 10.1159/000455850. Epub 2017 Mar 23. Horm Res Paediatr. 2017. PMID: 28334714 Review.
Cited by
-
ACAN Repeat Number Polymorphism in Patients with Idiopathic Short Stature.Cytogenet Genome Res. 2025;165(2):51-56. doi: 10.1159/000545736. Epub 2025 Jun 13. Cytogenet Genome Res. 2025. PMID: 40517756 Free PMC article.
-
Idiopathic Short Stature in the Genomic Era: Integrating Auxology, Endocrinology, and Emerging Genetic Insights.Children (Basel). 2025 Jun 27;12(7):855. doi: 10.3390/children12070855. Children (Basel). 2025. PMID: 40723048 Free PMC article. Review.
-
Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis.BMC Pediatr. 2025 Jan 13;25(1):28. doi: 10.1186/s12887-024-05356-z. BMC Pediatr. 2025. PMID: 39806319 Free PMC article.
-
Concurrent mutations in RNU4ATAC, PLEC, and CD96 in a child with severe short stature and skeletal dysplasia: a case report.Ital J Pediatr. 2025 Jul 15;51(1):226. doi: 10.1186/s13052-025-02054-z. Ital J Pediatr. 2025. PMID: 40660273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials